Evaluation of GLP-1 receptor agonists for type 2 diabetes treatment

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study aims to identify the most effective glucagon-like peptide-1 receptor agonists (GLP-1RAs) for adults with type 2 diabetes mellitus (T2DM). It employs a prospective cohort design, collecting comprehensive data on patients' demographics, lifestyle habits, hospitalization details, and diabetic complications. The study evaluates the safety, effectiveness, economy, innovation, appropriateness, and accessibility of GLP-1RAs in real-world settings to optimize their clinical application. The goal is to ensure these medications are utilized to their full potential while minimizing risks associated with their use.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Diagnosed with type 2 diabetes;
* no study drug has been used in the last three months;
* Existing hypoglycemic programs include investigational drugs;
* Age ≥18 years old;
* The patient's demographic data, disease history, course records, laboratory test indicators, drug use and other information were complete;
* Sign informed consent.

Exclusion Criteria:

* persistent influenza, autoimmune disease, or other metabolic disease;
* There are obvious gastrointestinal diseases, gastrointestinal resection or malabsorption syndrome;
* diet drugs, glucocorticoids, drugs affecting gastrointestinal motility are being used;
* Patients with severe liver and kidney function impairment and patients with malignant tumors;
* Pregnant or lactating women.

Where it's running

• Yan Li
  Jinan, China Recruiting

Study contacts

• Principal investigator: Yining Dong, pharmacist — Shandong Third Hospital
• Study coordinator: Dong Zhonghua The First Affiliated Hospital of Shandong First Medical Univer, master
• Email: dzh941213@163.com
• Phone: +8618253161252

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• HRS9531 tablets for adults with type 2 diabetes not controlled by lifestyle or metformin

  This trial tests whether HRS9531 tablets help people with type 2 diabetes who have not reached their blood sugar goals on lifestyle changes or on metformin alone.

  Recruiting at 2 sites Phase 2 Fujian Shengdi Pharmaceutical Co., Ltd. · Beijing, Beijing Municipality and 1 other locations · NCT07599410

• HM15275 in adults with type 2 diabetes who have not yet reached goal

  This phase 2 trial tests HM15275 or a placebo to see if it helps adults with type 2 diabetes improve blood sugar over 36 weeks.

  Recruiting at 20 sites Phase 2 Hanmi Pharmaceutical Company Limited · Mesa, Arizona and 19 other locations · NCT07527650

• HTD1801 vs placebo for kidney protection in type 2 diabetes and CKD

  This trial tests whether HTD1801 can slow kidney decline in adults with type 2 diabetes and chronic kidney disease.

  Recruiting Phase 2 Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences · Weifang, Shandong · NCT07496177

• Single-dose exenatide circular RNA in lipid nanoparticles for Chinese adults with type 2 diabetes

  This test gives a single injection of CR059 (exenatide circular RNA in a lipid nanoparticle) to see if it is safe and how it behaves in Chinese adults with type 2 diabetes.

  Recruiting Early Phase 1 The First Affiliated Hospital of Henan University of Science and Technology · Luoyang, Henan · NCT07347080

• Adding empagliflozin to alogliptin and metformin for type 2 diabetes

  This study tests whether adding empagliflozin to adults already taking alogliptin and metformin improves blood sugar control and is safe for people with type 2 diabetes who still have high blood sugar.

  Recruiting Phase 3 Celltrion · Seoul · NCT07093476

• Cofrogliptin every two weeks added to metformin and dapagliflozin versus daily linagliptin for type 2 diabetes

  This trial will test whether adding cofrogliptin every two weeks to metformin and dapagliflozin lowers HbA1c better than adding daily linagliptin in adults with type 2 diabetes whose blood sugar is not controlled on metformin plus an SGLT2 inhibitor.

  Recruiting at 2 sites Phase 4 Huazhong University of Science and Technology · Wuhan, Hubei and 1 other locations · NCT07019012

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.